Sun Pharmaceutical Industries Limited (SUNPHARMA) Q2 FY27 Financial Results: PAT ₹28,948 Cr & Revenue ₹1.52 L Cr

Sun Pharmaceutical reported Q1 FY27 revenue of INR1,51,836 million, up 10.1% YoY, with net profit at INR28,948 million and adjusted net profit of INR30,894 million. EBITDA stood at INR44,177 million, reflecting strong performance in innovative medicines (up 12.8% to USD351 million) and India (16% growth, 8.5% market share). U.S. generic sales declined 9.7% due to Lenalidomide loss, though new launches support future growth. Management highlighted pipeline progress, including semaglutide approvals in South Africa and Brazil, and sustained R&D investment at 5.4% of sales. Gross margin expansion is expected from product mix shifts, with full-year revenue growth guided at high single digits despite emerging market headwinds and forex volatility.